Open AccessDonanemab in Early Alzheimer’s Disease
Author(s) -
Mark A. Mintun,
Albert Lo,
Cynthia Evans,
Alette M. Wessels,
Paul Ardayfio,
Scott W. Andersen,
Sergey Shcherbinin,
JonDavid Sparks,
John R. Sims,
Mirosław Bryś,
Liana G. Apostolova,
Stephen Salloway,
Daniel Skovronsky
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2100708
Subject(s) - disease , medicine
A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom